Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2020 Earnings Conference Call - Final Transcript
Jul 30, 2020 • 08:30 am ET
Ladies and gentlemen, thank you for standing by. And welcome to the Blueprint Medicines Second Quarter 2020 Financial and Operating Results Conference Call. [Operator Instructions] I'd now like to hand the conference over to your speaker today, Kristin Hodous of Blueprint Medicines. Thank you. Please go ahead.
Thank you, operator. Good morning, everyone. And welcome to Blueprint Medicines Second Quarter 2020 Financial and Operating Results Conference Call. This morning, we issued a press release, which outlines the topics we plan to discuss today. You can access the press release, as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.
Today, on our call, Jeff Albers, our Chief Executive Officer, will discuss Blueprint Medicines second quarter 2020 business highlights; Christy Rossi, our Chief Commercial Officer, will provide a commercial update; and Mike Landsittel, our Chief Financial Officer, will review our financial results. Dr. Andy Boral, our Chief Medical Officer is also on the call and will be available for Q&A.
Before we get started, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our most recent quarterly report on Form 10-Q filed with the SEC and any other filings that we make with the SEC. In addition, any forward-looking statements made on this call represents our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.
Now, here's our CEO, Jeff Albers.
Thanks, Kristin, and good morning, everyone. I'm happy to provide an update on what has been a productive quarter for Blueprint Medicines. At the beginning of the year, we talked about how 2020 was shaping up to be transformational for Blueprint Medicines as we evolved into a fully integrated precision medicine company, and it certainly happened given the achievements we've made against our goals over the first half of the year.
Let me highlight how this progress sets us up going into the second half of the year across our three areas of strategic focus. First, establishing our commercial foundation with AYVAKIT, which we will now harness for pralsetinib; second, prioritizing systemic mastocytosis given the significant medical need; and third, leveraging our discovery platform to advance future pipeline opportunities.
Let's start off with a strong US AYVAKIT launch for the treatment of patients with PDGFR-alpha exon 18 mutant GIST. As Christy will discuss in a moment, we gained critical commercial experience and have built a nimble and highly effective team, along with infrastructure to deliver our products to patients. Our early experience with AYVAKIT gives us a strong foundation for our planned launch of pralsetinib in the coming months, which will now